SCHEMBL13435561

SCHEMBL13435561

Cc1ccc2nc(CC3CCCC3)[nH]c2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.63
▸ IDO1 P14902 4/20 0.62
▸ KMT2A Q03164 4/20 0.62
▸ POLB P06746 3/20 0.62
▸ NPC1 O15118 4/20 0.58
▸ RAB9A P51151 4/20 0.58
▸ CYP1A2 P05177 2/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ GRIN1 Q05586 1/20 0.51
▸ GRIN2B Q13224 1/20 0.51
▸ MEN1 O00255 2/20 0.50
▸ GFER P55789 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21034524 0.87 AAK1 (0.51) AAK1IDO1KMT2APOLBNPC1
SCHEMBL23005703 0.81 AAK1 (0.59) AAK1IDO1KMT2APOLBNPC1
SCHEMBL23005583 0.80 AAK1 (0.57) AAK1IDO1CYP1A2CYP3A4CYP2D6
SCHEMBL21034171 0.80 MEN1 (0.57) AAK1IDO1KMT2ACYP1A2CYP3A4
SCHEMBL4111972 0.78 IDO1 (0.70) AAK1IDO1POLBNPC1RAB9A
SCHEMBL10142439 0.77 KMT2A (0.74) KMT2APOLBNPC1RAB9ACYP1A2
SCHEMBL6759257 0.76 IDO1 (0.68) AAK1IDO1POLBNPC1RAB9A
SCHEMBL18765332 0.76 KMT2A (0.72) KMT2APOLBNPC1RAB9ACYP1A2
SCHEMBL15947556 0.76 KMT2A (0.72) KMT2APOLBNPC1RAB9ACYP1A2
SCHEMBL1971259 0.75 KMT2A (0.61) IDO1KMT2APOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 — — US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP AAK1 2970/4885IDO1 1290/4885KMT2A 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback